Mesenchymal stem cells reduce cigarette smoke-induced inflammation and airflow obstruction in rats via TGF-β1 signaling

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 5, 2014, Pages 582-590

  Song, Lin ^a   Guan, Xiao Jun ^a   Chen, Xi ^a   Cui, Zhi Lei ^a   Han, Feng Feng ^a   Guo, Xue Jun ^a   Xu, Wei Guo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Inflammation; Mesenchymal stem cell; Transforming growth factor 1

Indexed keywords

BETA1 INTEGRIN; CD11B ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CIGARETTE SMOKE; ENDOGLIN; GLYCOPROTEIN P 15095; HERMES ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; AUTACOID; CYTOKINE; SMOKE; TGFB1 PROTEIN, RAT;

AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CELL CULTURE; CLINICAL EVALUATION; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATORY CELL; LEUKOCYTE DIFFERENTIAL COUNT; LUNG FUNCTION; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ADVERSE EFFECTS; ANIMAL; CELL COUNT; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; LUNG LAVAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MONONUCLEAR CELL; SMOKE; SPRAGUE DAWLEY RAT; TOBACCO; TRACHEA;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; COCULTURE TECHNIQUES; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMOKE; TOBACCO; TRACHEA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84929940450     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.898032     Document Type: Article

References (46)

1. Pa RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364:613–620.
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532–555.
3. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 2012; 122(8):2749–2755.
4. Nikota JK, Stampfli MR. Cigarette smoke-induced inflammation and respiratory host defense: Insights from animal models. Pulm Pharmacol Th er 2012; 25(4):257–262.
5. Abreu SC, Antunes MA, Pelosi P, et al. Mechanisms of cellular therapy in respiratory diseases. Intensive Care Med 2011; 37(9):1421–1431.
6. Sinclair K, Yerkovich ST, Chambers DC. Mesenchymal stem cells and the lung. Respirology 2013; 18(3):397–411.
7. Aliotta JM, Passero M, Meharg J, et al. Stem cells and pulmonary metamorphosis: New concepts in repair and regeneration. J Cell Physiol 2005; 204:725–741.
8. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15(1):42–49.
9. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179:1855–1863.
10. D’Agostino B, Sullo N, Siniscalco D, et al. Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease. Expert Opin Biol Th er 2010; 10(5):681–687.
11. Katsha AM, Ohkouchi S, Xin H, et al. Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastaseinduced emphysema model. Mol Th er 2011; 19(1):196–203.
12. Iyer SS, Co C, Rojas M. Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med 2009; 51(1):5–16.
13. Lee JW, Gupta N, Serikov V, et al. Potential application of mesenchymal stem cells in acute lung injury. Expert Opin Biol Th er 2009; 9(10):1259–1270.
14. Kean TJ, Lin P, Caplan AI, et al. MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation. Stem Cells Int 2013; 2013:732–742.
15. Matthay MA, Th ompson BT, Read EJ, et al. Th erapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest 2010; 138(4):965–972.
16. Xu J, Woods CR, Mora AL, et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 2007; 293:L131–141.
17. Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013; 143(6):1590–1598.
18. Gao J, Zhan B. The effects of Ang-1, IL-8 and TGF-β1 on the pathogenesis of COPD. Mol Med Rep 2012; 6(5):1155–1159.
19. Konigshoff M, Kneidinger N, Eickelberg O. TGF-beta signaling in COPD: deciphering genetic and cellular susceptibilities for future therapeutic regimen. Swiss Med Wkly 2009; 139:554–563.
20. Morty RE, Konigshoff M, Eickelberg O. Transforming growth factor-beta signaling across ages: from distorted lung development to chronic obstructive pulmonary disease. Proc Am Th orac Soc 2009; 6(7):607–613.
21. Roberts AB. Medicine: Smoke signals for lung disease. Nature 2003; 422:130–131.
22. Morris DG, Huang X, Kaminski N, et al. Loss of integrin alpha(v) beta6-mediated TGFbeta activation causes Mmp12-dependent emphysema. Nature 2003; 422:169–173.
23. Zhen G, Xue Z, Zhao J, et al. Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. Cytotherapy 2010; 12:605–614.
24. Katsha AM, Ohkouchi S, Xin H, et al. Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastaseinduced emphysema model. Mol Th er 2011; 19:196–203.
25. Huh JW, Kim SY, Lee JH, et al. Bone marrow cells repair cigarette smoke-induced emphysema in rats. Am J Physiol Lung Cell Mol Physiol 2011; 301:L255–266.
26. Guan XJ, Song L, Han FF, et al. Mesenchymal stem cells protect cigarette smoke-damaged lung and pulmonary funtion partly via VEGF-VEGF receptors. J Cell Biochem 2013; 114(2):323–335.
27. Vanoirbeek JA, Rinaldi M, De Vooght V, et al. Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol 2010; 42:96–104.
28. Yao H, Edirisinghe I, Rajendrasozhan S, et al. Cigarette smokemediated inflammatory and oxidative responses are straindependent in mice. Am J Physiol Lung Cell Mol Physiol 2008; 294:L1174–1186.
29. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Th e International Society for Cellular Th erapy position statement. Cytotherapy 2006; 8:315–317.
30. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378(9795):1015–1026.
31. Shapiro SD. Transgenic and gene-targeted mice as models for chronic obstructive pulmonary disease. Eur Respir J 2007; 29:375–378.
32. Salem HK, Th iemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010; 28:585–596.
33. Lee JW, Gupta N, Serikov V, et al. Potential application of mesenchymal stem cells in acute lung injury. Expert Opin Biol Ther 2009; 9(10):1259–1270.
34. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22:672–688.
35. Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007; 87:1047–1082.
36. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Th orax 2010; 65:930–936.
37. Lakhdar R, Denden S, Kassab A, et al. Update in chronic obstructive pulmonary disease: role of antioxidant and metabolizing gene polymorphisms. Exp Lung Res 2011; 37:364–375.
38. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis 2011; 6:413–421.
39. Yang YC, Zhang N, Van Crombruggen K, et al. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy 2012; 67(10):1193–1202.
40. Budd DC, Holmes AM. Targeting TGFβ superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders. Pharmacol Th er 2012; 135(3):279–291.
41. Zandvoort A, Postma DS, Jonker MR, et al. Altered expression of the Smad signaling pathway: implications for COPD pathogenesis. Eur Respir J 2006; 28:533–541.
42. Baraldo S, Bazzan E, Turato G, et al. Decreased expression of TGF-β type II receptor in bronchial glands of smokers with COPD. Th orax 2005; 60:998–1002.
43. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359:693–699.
44. Morris DG, Huang X, Kaminski N, et al. Loss of integrin αvβ6-mediated TGF-β activation causes Mmp12-dependent emphysema. Nature 2003; 422:169–173.
45. Lixuan Z, Jingcheng D, Wenqin Y, Jianhua H, Baojun L, Xiaotao F. Baicalin attenuates inflammation by inhibiting NK-κB activation in cigarette smoke induced inflammatory models. Pulm Pharmacol Th er 2010; 23:411–419.
46. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378:1015–1026.